| Substitute for form 1449A/PTO | Complete if Known | | | |
|-----------------------------------|------------------------|-----------|-------------|--|
| | Application Number | | | |
| INFORMATION DISCLOSURE | Filing Date | | | |
| STATEMENT BY APPLICANT | First Named Inventor | Thomas N. | THOMAS | |
| OTATEMEN, DI ALI EIOANI | Art Unit | | | |
| (Use as many sheets as necessary) | Examiner Name | | | |
| Sheet | Attorney Docket Number | | | |

| | | | U.S. PATENT D | OCUMENTS | |
|--|--------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No.¹ | Document Number Number-Kind Code ^{2 (# known)} | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | us-6, 432, 991 | 08-13-2002 | Thomas TN | pages 1-13 · |
| | | us-6,635,667 | 10-21-2003 | Thomas, TN | Pages 1-13 |
| | | US-6,482,846 | 11-19-2002 | Garvey DS, et al | Pages (-33 |
| | | us. 6, 593, 347 | 07-15-2003 | Bandazage UK, et al. | pages 1-15 |
| | | US-6,544,556 | 04-08-2003 | Chen CM, et al | pages 1-14 |
| | | us-6, 613, 784 | 09-02-2003 | Bonedini F, et al | Pages 1-10 |
| , <u>1888 - 1888 -</u> | | US-6,649,629 | 11-18-2003 | Bandarage UK etal | pages 1-40 |
| | | US- | | , , , | , 0 |
| | | US- | | and the state of the second | |
| | | US- | , | | |
| | | US- | | | *** |
| | <u> </u> | US- | | ar a respiratore. Mi son al 1 simil o Maksania tako asanditsa - deritti di 1000-100-100 A 100-100 (100) | ** *********************************** |
|) es d su suado madena condicio su | | US- | | | |
| | | US- | | n garata ana a a sa a tha an dheach anns and a dheach anns an anns a dheach | *************************************** |
| | | US- | | e maniferia inde about delenio destina antificialisti est discondibunato restito i telas i residendos i mestes | |
| | <u> </u> | US- | | | |
| | | US- | | | |
| | | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------|---|--|--|---|----|
| Examiner Initials* | Cite No.1 | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | 76 |
| | | Country Code ³ Number ⁴ 'Kind Code ⁵ (<i>if known</i>) | | | or Relevant Figures Appear | |
| | | | ······································ | *************************************** | *************************************** | Н |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| Substitute form 1449B/PTO | | Complete If Known |
|-----------------------------------|------------------------|-------------------|
| | Application Number | |
| INFORMATION DISCLOSURE | Filing Date | Thomas N. Thomas |
| STATEMENT BY APPLICANT | First Named Inventor | THOMAS N. THOMAS |
| | Art Unit | |
| (Use as many sheets as necessary) | Examiner Name | |
| Sheet of | Attorney Docket Number | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|---|--------------|---|----------------|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| *************************************** | 1 | Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med, 346: 1468-1474, 2002. | 1 |
| ******************************* | 2 | Fennerty BM. NSAID-related gastrointestinal injury. Postgraduate Medicine, 110: 87-94, 2001. | |
| ************************** | 3 | Yeomans ND. Approaches to healing and prophylaxis of nonsteroidal antiinflammatory Drug-associated ulcers. Am. J. Medicine. 110/1A: 24S - 28S, 2001 | / |
| ******************************* | 4 | GlavinGB, et al. L-deprenyl attennuates stress ulcer formation in rats. Neurosci. Letters. 70: 379-381 (1986). | / |
| | 5 | ThyagaRajan S. Anti-tumor effect of l-deprenylin rats with carcinogen-induced Mammary tumors. J. Neuroimmunol. 109: 95-104, 2000. | / |
| | 6 | Thomas, T; et al. L-Deprenyl: nitric oxide productionand dilation of cerebral blood vessels. NeuroReport, 9:1-6, 1998 | / |
| | 7 | Thomas, T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol. Aging. 21:343-348, 2000. | √ |
| | 8 | Thomas T,et al. Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal Antiinflammatory drugs. Exp Clin Endocrinol Diabetes. 111: 8-11, 2003. | / |
| | 9 | Thomas, T. et al. Inhibition of LDL oxidation by the neuroprotective drug 1-deprenyl. Neurol. Res. 24:169-173, 2002 | √ |
| | 10 | Wallace JL and Soldato DL. The therapeutic potential of NO-NSAIDS. Fundamental & Clin Pharmacol. 17: 11-20, 2003. | $\sqrt{}$ |

| 7 | | | | |
|-----------|---|---|-------------|-----|
| Examiner | , | • | 8-1- | |
| Signature | 1 | | Date | |
| Signature | | | Considered | · · |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not clause is in conformance with interest obs. Draw line through clause the considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, precading and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any commenta os Pro to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 URK 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.